Auspex Pharmaceuticals Overview
- Year Founded
-
2001
- Status
-
Acquired/Merged
- Employees
-
37
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$3.5B
Auspex Pharmaceuticals General Information
Description
Developer of deuterated analogs of clinically-validated drugs. The company develops a pipeline of therapeutics that improves on existing drugs across various therapeutic areas. It focuses on the development of drugs for the treatment of involuntary movement disorders, respiratory disease and inflammation.
Contact Information
Website
www.auspexpharma.comCorporate Office
- 3366 North Torrey Pines Court
- Suite 225
- San Diego, CA 92037
- United States
Corporate Office
- 3366 North Torrey Pines Court
- Suite 225
- San Diego, CA 92037
- United States
Auspex Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 16. Merger/Acquisition | 05-May-2015 | $3.5B | Completed | Clinical Trials - Phase 3 | ||
| 15. 2PO | 23-Jan-2015 | Completed | Clinical Trials - Phase 3 | |||
| 14. 2PO | 11-Jul-2014 | Completed | Clinical Trials - Phase 3 | |||
| 13. IPO | 05-Feb-2014 | Completed | Clinical Trials - Phase 3 | |||
| 12. Debt - General | 08-Jan-2014 | Completed | Clinical Trials - Phase 3 | |||
| 11. Later Stage VC (Series E) | 20-Dec-2013 | Completed | Clinical Trials - Phase 3 | |||
| 10. Later Stage VC (Series D) | 06-Sep-2013 | Completed | Clinical Trials - Phase 3 | |||
| 9. Debt - General | 11-Mar-2013 | Completed | Clinical Trials - Phase 3 | |||
| 8. Later Stage VC | 09-Nov-2012 | $19M | $70M | Completed | Clinical Trials - Phase 3 | |
| 7. Later Stage VC | 28-Dec-2011 | $3M | $51M | Completed | Generating Revenue |
Auspex Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series E | ||||||||
| Series D | ||||||||
| Series C | ||||||||
| Series B | ||||||||
| Series A5 | ||||||||
| Series A4 | ||||||||
| Series A3 | ||||||||
| Series A2 | 610,294 | $0.000100 | 8% | $1.7 | $1.7 | 1x | $1.7 | 0.87% |
| Series A1 | 613,500 | $0.000100 | 8% | $1 | $1 | 1x | $1 | 0.88% |
Auspex Pharmaceuticals Comparisons
Industry
Financing
Details
Auspex Pharmaceuticals Competitors (93)
One of Auspex Pharmaceuticals’s 93 competitors is Cirius Therapeutics, a Venture Capital-Backed company based in Grand Rapids, MI.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Cirius Therapeutics | Venture Capital-Backed | Grand Rapids, MI | ||||
| Scynexis | Formerly VC-backed | Jersey City, NJ | ||||
| Astellas Pharma | Corporation | Tokyo, Japan | ||||
| Biosplice Therapeutics | Private Equity-Backed | San Diego, CA | ||||
| Gossamer Bio | Formerly VC-backed | San Diego, CA |
Auspex Pharmaceuticals Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Auspex Pharmaceuticals Patents
Auspex Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4536181-A1 | Osmotic dosage forms comprising deutetrabenazine and methods of use thereof | Pending | 08-Jun-2022 | ||
| WO-2023240186-A1 | Osmotic dosage forms comprising deutetrabenazine and methods of use thereof | Inactive | 08-Jun-2022 | ||
| AU-2022346033-A1 | Multiparticulate dosage forms comprising deutetrabenazine | Pending | 17-Sep-2021 | ||
| CA-3231490-A1 | Multiparticulate dosage forms comprising deutetrabenazine | Pending | 17-Sep-2021 | ||
| EP-4401707-A1 | Multiparticulate dosage forms comprising deutetrabenazine | Pending | 17-Sep-2021 | A61K9/5078 |
Auspex Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Auspex Pharmaceuticals Former Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| BioMed Ventures | Corporate Venture Capital | Minority | ||
| Costa Verde Capital | Venture Capital | Minority | ||
| Deerfield Management | Venture Capital | Minority | ||
| Foresite Capital | Growth/Expansion | Minority | ||
| Panorama Capital | Venture Capital | Minority |
Auspex Pharmaceuticals ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Auspex Pharmaceuticals FAQs
-
When was Auspex Pharmaceuticals founded?
Auspex Pharmaceuticals was founded in 2001.
-
Where is Auspex Pharmaceuticals headquartered?
Auspex Pharmaceuticals is headquartered in San Diego, CA.
-
What is the size of Auspex Pharmaceuticals?
Auspex Pharmaceuticals has 37 total employees.
-
What industry is Auspex Pharmaceuticals in?
Auspex Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Auspex Pharmaceuticals a private or public company?
Auspex Pharmaceuticals is a Private company.
-
What is the current valuation of Auspex Pharmaceuticals?
The current valuation of Auspex Pharmaceuticals is .
-
What is Auspex Pharmaceuticals’s current revenue?
The current revenue for Auspex Pharmaceuticals is .
-
How much funding has Auspex Pharmaceuticals raised over time?
Auspex Pharmaceuticals has raised $493M.
-
Who are Auspex Pharmaceuticals’s investors?
BioMed Ventures, Costa Verde Capital, Deerfield Management, Foresite Capital, and Panorama Capital are 5 of 9 investors who have invested in Auspex Pharmaceuticals.
-
Who are Auspex Pharmaceuticals’s competitors?
Cirius Therapeutics, Scynexis, Astellas Pharma, Biosplice Therapeutics, and Gossamer Bio are some of the 93 competitors of Auspex Pharmaceuticals.
-
When was Auspex Pharmaceuticals acquired?
Auspex Pharmaceuticals was acquired on 05-May-2015.
-
Who acquired Auspex Pharmaceuticals?
Auspex Pharmaceuticals was acquired by Teva Pharmaceutical Industries.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
